Polyol-hormone mixture for use in chronic parenteral hormone administration

• US 4,439,181 A
• Filed: 01/26/1981
• Issued: 03/27/1984
• Est. Priority Date: 01/26/1981
• Status: Expired due to Term

• Current Assignee: Regents of The University of Minnesota (University of Minnesota)
• Original Assignee: Regents of The University of Minnesota (University of Minnesota)
• Inventors: Rohde, Thomas D., Blackshear, Perry J., Palmer, John L.
• Primary Examiner(s): Rosenbaum, C. Fred
• Assistant Examiner(s): Wallen, T. J.
• Application Number:
  US06/228,097
• Time in Patent Office: 1,156 Days
• Field of Search: 128/213 A, 128/213 R, 128/260, 128/214 R, 128/260, 128/214 F, 260/210, 604/27-28, 604/48-53, 604/56, 604/82-84, 604/92
• US Class Current: 604/518
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00

Abstract

A method of preventing the precipitation of proteins, such as hormone preparations, within drug delivery systems that depend on the fluidity of the infusate for proper function. A polyol, such as glycerol, is mixed with the protein solution prior to the introduction of the solution into the drug delivery system. The polyol is added in amount sufficient to prevent precipitation of the protein during long-term storage in the drug delivery device. According to one form of usage, the protein-polyol solution is injected to the pressurized drug storage reservoir of an implanted infusion pump by injection through the patient'"'"'s skin. As the solution is discharged from the delivery device by the constant pressure exerted upon the storage chamber, its low rate of flow is controlled by a restricted fluid passage. The solution is conveyed to an infusion site and diluted by the blood stream.

Claims

1. A method of maintaining the fluidity of protein solutions for parenteral administration at a low flow rate to a chronically ill patient suffering from a protein-deficiency disease from a drug delivery device that depends on the fluidity of the infusate for proper functioning, without loss of biological activity, which method comprises:

(A) dissolving an effective amount between about 10 and 90 percent by weight/volume, sufficient to prevent precipitation of the protein, of a biocompatible C-4 to C-18 polyol in the protein solution prior to injection into the drug storage chamber of the delivery device, and

(B) charging the drug storage chamber of the drug delivery device with said protein-polyol solution.

2. A method according to claim 1 wherein said protein is a hormone.

3. A method according to claim 2 wherein said hormone is insulin.

4. A method according to claim 1 wherein said drug delivery device is an implanted pressure actuated device whose storage chamber is charged by injection of the protein-polyol solution through the skin of the patient.

5. A method according to claim 1 wherein said polyol is glycerol present in amount between about 10 and 90 percent by volume.

6. A method according to claim 5 wherein said glycerol is present in amount between about 50 and 80 percent by volume.

7. A method according to claim 1 wherein said polyol is a solid selected from the class consisting of ribose, xylose, mannose, fructose and sorbose present in amount between about 10 and 90 percent by weight.

9. A method according to claim 2 wherein said protein is a hormone.

10. A method according to claim 9 wherein said hormone is insulin.

11. A method according to claim 2 wherein said drug delivery device is an implanted pressure actuated device whose storage chamber is charged by injection of the protein-polyol solution through the skin of the patient.

8. A method of administering a protein solution at a low flow rate to a chronically ill patient suffering from a protein-deficiency disease, which method comprises:

(A) dissolving an effective amount between about 10 and 90 percent by weight/volume, sufficient to prevent precipitation of the protein, of a biocompatible C-4 to C-18 polyol in the protein solution to maintain the fluidity of the solution without loss of biological activity,

(B) charging the drug storage chamber of a drug delivery device that depends on the fluidity of the infusate for proper functioning with the protein-polyol solution,

(C) continuously discharging the solution from the storage chamber through a restricted flow passage into the blood stream of the patient at a rate between about 1 cc and 15 cc solution per day, and

(D) diluting the solution with the blood stream as it enters the blood stream.

12. A method according to claim 8 wherein said polyol is glycerol present in amount between about 10 and 90 percent by volume.

14. A method according to claim 8 wherein said polyol is a solid selected from the class consisting of ribose, xylose, mannose, fructose and sorbose present in amount between about 10 and 90 percent by weight.

13. A method according to claim 16 wherein said glycerol is present in amount between about 50 and 80 percent by volume.